skip to Main Content

So finden Sie uns!

Das Westdeutsche Herz- und Gefäßzentrum Essen mit der Klinik für Kardiologie und Angiologie befindet sich auf dem Gelände des Universitätsklinikums Essen. Sollten Sie die Routenplanung selbst vornehmen wollen, dann schauen Sie unsere Wegbeschreibung oder benutzen Sie bitte folgende Postadresse:

Hufelandstr. 55 | 45122 Essen

Bleiben sie mit uns in Kontakt

Fax: +49 (201) 723 - 5480
Lageplan des Klinikums

Standort

E-Mail: Andrea.Odersky@uk-essen.de
Office: MFZ 3. OG Room 03.026
Telefon: +49 201 723 6011
Fax: +49 201 723 6973
Andrea Odersky

BIO

Andrea Odersky finished her education to Technical Assistant of Biology (BTA) at the Rheinische Akademie e.V., Köln after 2 years in 1994. Her career as Research Technician started at the Opthalmology Institut at the University Hospital Cologne. Futhermore she was trained in 4 other labs with different focus in research: Institute of Cell Biology (University Hospital Essen), Departement of Genetic (University Duisburg-Essen), Institute of Molecular Biology and Biochemistry II (Heinrich-Heine-University Düsseldorf) and Department of Pediatric Oncology (University Children´s Hospital Essen).
With a broad spectrum of different techniques she supports the CardioScienceLabs since November 2015.

RESEARCH INTERESTS

Proteomics, Genomics, Cell Culture, Mouse Core, Drug discovery, Cancer, Epigenetics, Anatomy, Good laboratory practise (GLP), Lab management

PUBLICATIONS

  • Han Y, Lindner S, Bei Y, Garcia HD, Timme N, Althoff K, Odersky A, Schramm A, Lissat A, Künkele A, Deubzer HE, Eggert A, Schulte JH, Henssen AG. Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma. Cancer Lett. 2019, 445:24-33.
  • Gottlieb A, Althoff K, Grunewald L, Thor T, Odersky A, Schulte M, Deubzer HE, Heukamp L, Eggert A, Schramm A, Schulte JH, Künkele A. RITA displays anti-tumor activity in medulloblastomas independent of TP53 status. Oncotarget. 2017, 27882-27891.
  • Pajtler KW, Sadowski N, Ackermann S, Althoff K, Schönbeck K, Batzke K,Schäfers S, Odersky A, Heukamp L, Astrahantseff K, Künkele A, Deubzer HE, Schramm A, Sprüssel A, Thor T, Lindner S, Eggert A, Fischer M, Schulte JH. The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models. Oncotarget. 2017, 6730-6741.
  • Henssen AG, Odersky A, Szymansky A, Seiler M, Althoff K, Beckers A, Speleman F, Schäfers S, De Preter K, Astrahanseff K, Struck J, Schramm A, Eggert A, Bergmann A, Schulte JH. Targeting tachykinin receptors in neuroblastoma. Oncotarget. 2017, 430-443.
  • Henssen AG, Althoff K, Odersky A, Beckers A, Koche R, Speleman F, Schaefer S, Bell E, Nortmeyer M, Westermann F, De Preter K, Florin A, Heukamp L, Spruessel A,Astrahanseff K, Lindner S, Solomentsew N, Schramm A, Astorgues-Xerri L, RiveiroME, Eggert A, Cvitkovic E, Schulte JH. 2015 – Targeting MYCN-driven transcription byBET-bromodomain inhibition. Clin Cancer Res. pii:clincanres.1449.2015. [Epub ahead of print]
  • Lindner S, Bachmann HS, Odersky A, Schaefers S, Klein-Hitpass L, Hero B, Fischer M, Eggert A, Schramm A, Schulte JH. 2015 – Absence of telomerase reverse transcriptase promoter mutations in neuroblastoma. Biomed Rep. 3:443-446.
  • Schramm A, Köster J, Assenov Y, Althoff K, Peifer M, Mahlow E, Odersky A,Beisser D, Ernst C, Henssen AG, Stephan H, Schröder C, Heukamp L, Engesser A,Kahlert Y, Theissen J, Hero B, Roels F, Altmüller J, Nürnberg P, Astrahantseff K,Gloeckner C, De Preter K, Plass C, Lee S, Lode HN, Henrich KO, Gartlgruber M,Speleman F, Schmezer P, Westermann F, Rahmann S, Fischer M, Eggert A, Schulte JH. 2015 – Mutational dynamics between primary and relapse neuroblastomas. Nat Genet. 47:872-7.
  • Pajtler KW, Mahlow E, Odersky A, Lindner S, Stephan H, Bendix I, Eggert A,Schramm A, Schulte JH. 2014 – Neuroblastoma in dialog with its stroma: NTRK1 is aregulator of cellular cross-talk with Schwann cells. Oncotarget. 5:11180-92.
  • Althoff K, Lindner S, Odersky A, Mestdagh P, Beckers A, Karczewski S, MolenaarJJ, Bohrer A, Knauer S, Speleman F, Epple M, Kozlova D, Yoon S, Baek K,Vandesompele J, Eggert A, Schramm A, Schulte JH. 2015 – miR-542-3p exerts tumor suppressive functions in neuroblastoma by downregulating Survivin. Int J Cancer. 136:1308-20.
  • Pfeiffer P, Odersky A, Goedecke W, Kuhfittig-Kulle S. 2014 – Analysis of double-strand break repair by nonhomologous DNA end joining in cell-free extracts from mammalian cells. Methods Mol Biol. 1105:565-85.
  • Henssen A, Thor T, Odersky A, Heukamp L, El-Hindy N, Beckers A, Speleman F, Althoff K, Schäfers S, Schramm A, Sure U, Fleischhack G, Eggert A, Schulte JH. 2013 – BET bromodomain protein inhibition is a therapeutic option for medulloblastoma. Oncotarget. 4:2080-95.
  • Althoff K, Beckers A, Odersky A, Mestdagh P, Köster J, Bray IM, Bryan K, Vandesompele J, Speleman F, Stallings RL, Schramm A, Eggert A, Sprüssel A, Schulte JH. 2013 – MiR-137 functions as a tumor suppressor in neuroblastoma by downregulating KDM1A. Int J Cancer. 133:1064-73.
  • Heukamp LC, Thor T, Schramm A, De Preter K, Kumps C, De Wilde B, Odersky A, Peifer M, Lindner S, Spruessel A, Pattyn F, Mestdagh P, Menten B, Kuhfittig-Kulle S, Künkele A, König K, Meder L, Chatterjee S, Ullrich RT, Schulte S, Vandesompele J, Speleman F, Büttner R, Eggert A, Schulte JH. 2012 – Targeted expression of mutated ALK induces neuroblastoma in transgenic mice. Sci Transl Med. 4:141ra91.
  • Kuhfittig-Kulle S, Feldmann E, Odersky A, Kuliczkowska A, Goedecke W, Eggert A, Pfeiffer P. 2007 – The mutagenic potential of non-homologous end joining in the absence of the NHEJ core factors Ku70/80, DNA-PKcs and XRCC4-LigIV. Mutagenesis. 22:217-33.
  • Pfeiffer P, Feldmann E, Odersky A, Kuhfittig-Kulle S, Goedecke W. 2005 – Analysis of DNA double-strand break repair by nonhomologous end joining in cell-free extracts from mammalian cells. Methods Mol Biol. 291:351-71.
  • Odersky A, Panyutin IV, Panyutin IG, Schunck C, Feldmann E, Goedecke W, Neumann RD, Obe G, Pfeiffer P. 2002 – Repair of sequence-specific 125I-induced double-strand breaks by nonhomologous DNA end joining in mammalian cell-free extracts. J Biol Chem. 277:11756-64.
Back To Top